MarketCapExport financials
NextCure (NXTC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
NextCure Balance Sheet 2025-2011 | NXTC
Brief overview of NextCure's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
Assets finished at $50.2 million versus $242.4 million initially, losing -79.3%. The balance sheet contracted.
Liabilities expanded faster than the asset base, +69.3% versus -79.3%. Debt-service capacity deserves attention.
The equity ratio reached 69.6% from 96.3%. A high capital share reduces dependence on liabilities.
The balance sheet holds more cash than interest-bearing debt; net debt is -$20.8 million, indicating minimal leverage.
Cash accounts for 51.8% of assets versus 5.1% initially. The change indicates the degree of financial flexibility.
The balance sheet carries negative retained earnings of -$436 million. The figure may result from accumulated losses or an active capital return policy.
Overall picture
NextCure's balance sheet profile is moderate. It should be considered alongside profitability, cash flow and liability maturities.
Annual Balance Sheet NextCure
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-20.8 M | -21.8 M | -6.48 M | -19.5 M | - | -29.3 M | -29.1 M | -135 M | -7.57 M | - | - | - | - | - | - |
Long Term Debt |
4.15 M | 5.15 M | 5.95 M | 6.6 M | - | 1.81 M | 3.33 M | 73 K | 460 K | - | - | - | - | - | - |
Long Term Debt Current |
1 M | 796 K | 656 K | 518 K | - | 1.67 M | 1.67 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | 2.6 M | - | 184 M | 40.8 M | - | - | - | - | - | - |
Total Current Liabilities |
10.6 M | 9.57 M | 6.88 M | 9.13 M | 6.61 M | 10.3 M | 15 M | - | - | - | - | - | - | - | - |
Total Liabilities |
15.2 M | 15.4 M | 13.6 M | 16.6 M | 9 M | 12.9 M | 34.7 M | 195 M | 43.9 M | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 4.99 M | - | - | - | - | - | - | - |
Retained Earnings |
-436 M | -380 M | -324 M | -262 M | -187 M | -118 M | -81 M | -47.3 M | -24.5 M | - | - | - | - | - | - |
Total Assets |
50.2 M | 80.9 M | 128 M | 184 M | 242 M | 307 M | 356 M | 148 M | 19.5 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
26 M | 27.7 M | 13.1 M | 26.6 M | 12.3 M | 32.8 M | 34.1 M | 136 M | - | - | - | - | - | - | - |
Book Value |
34.9 M | 65.5 M | 114 M | 168 M | 233 M | 294 M | 321 M | -46.9 M | -24.4 M | - | - | - | - | - | - |
Total Shareholders Equity |
34.9 M | 65.5 M | 114 M | 168 M | 233 M | 294 M | 321 M | -46.9 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet NextCure
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
3.6 M | 3.88 M | 4.41 M | 4.67 M | 4.91 M | 5.15 M | 5.39 M | 5.59 M | 5.77 M | 5.95 M | 6.12 M | 6.29 M | 6.45 M | 6.6 M | - | - | - | - | - | 972 K | 1.39 M | 1.81 M | 1.81 M | 1.81 M | 1.81 M | 3.33 M | 3.33 M | 3.33 M | 3.33 M | 73 K | 73 K | 73 K | 73 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
10.5 M | 11.3 M | 16 M | 16 M | 11.3 M | 15.4 M | 14.8 M | 17.1 M | 16.1 M | 13.6 M | 13.5 M | 15 M | 13.6 M | 16.6 M | 8.37 M | - | 8.81 M | 9 M | 9.6 M | 11.8 M | 11.8 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 34.7 M | 34.7 M | 34.7 M | 34.7 M | 32.3 M | 32.3 M | 32.3 M | 32.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-461 M | -446 M | -427 M | -418 M | -391 M | -380 M | -369 M | -357 M | -342 M | -324 M | -310 M | -296 M | -278 M | -262 M | -244 M | - | -208 M | -187 M | -170 M | -152 M | -134 M | -118 M | -118 M | -118 M | -118 M | -81 M | -81 M | -81 M | -81 M | -47.3 M | -47.3 M | -47.3 M | -47.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
22.6 M | 38 M | 39.6 M | 47.7 M | 67.1 M | 80.9 M | 90.3 M | 103 M | 115 M | 128 M | 140 M | 153 M | 168 M | 184 M | 190 M | - | 223 M | 242 M | 258 M | 275 M | 291 M | 307 M | 307 M | 307 M | 307 M | 356 M | 356 M | 356 M | 356 M | 148 M | 148 M | 148 M | 148 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
15.3 M | 15.2 M | 7.32 M | 4.89 M | 21.8 M | 27.7 M | 27.7 M | 20.8 M | 18.4 M | 13.1 M | 19.5 M | 22 M | 30 M | 26.6 M | 31.1 M | 28.2 M | 10.7 M | 12.3 M | 36.7 M | 34.9 M | 36.5 M | 32.8 M | 32.8 M | 32.8 M | 32.8 M | 34.1 M | 34.1 M | 34.1 M | 34.1 M | 135 M | 135 M | 135 M | 135 M | 9.29 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
12.1 M | 26.7 M | 23.6 M | 31.6 M | 55.9 M | 65.5 M | 75.6 M | 85.4 M | 99 M | 114 M | 126 M | 138 M | 154 M | 168 M | 182 M | - | 214 M | 233 M | 248 M | 264 M | 279 M | 294 M | 294 M | 294 M | 294 M | 321 M | 321 M | 321 M | 321 M | 115 M | 115 M | 115 M | 115 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
12.1 M | 26.7 M | 23.6 M | 29.6 M | 55.9 M | 65.5 M | 75.6 M | 85.4 M | 99 M | 114 M | 126 M | 138 M | 154 M | 168 M | 182 M | 198 M | 214 M | 233 M | 248 M | 264 M | 279 M | 294 M | 294 M | 294 M | 294 M | 321 M | 321 M | 321 M | 321 M | -46.9 M | -46.9 M | -46.9 M | -46.9 M | -24.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of NextCure, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
France
Israel
Australia
Danmark
Irlanda
